ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
AN2 Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.37−0.01 (-0.30%)
Close on Oct 19, 2026
- Market cap
- $150.84M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.18 (+183.2%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $150.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.99
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$36.24M
- EPS, diluted
- -$1.07
- Book value per share
- $1.70
- Diluted shares
- 45M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
-$38.81M
Net income
-$36.24M
EPS, diluted
-$1.07
Reported periodTrailing twelve months